Quviviq (daridorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1].
What is the mechanism of action for Quviviq?
Quviviq works by blocking the activity of orexin neuropeptides, specifically orexin-1 and orexin-2 receptors. Orexins are key regulators of wakefulness. By inhibiting these receptors, Quviviq reduces the wake-drive, thereby promoting sleep [1].
How is Quviviq administered and what are the typical dosages?
Quviviq is taken orally. The recommended dosage for adults is 25 mg once nightly. In some cases, a dosage of 12.5 mg may be considered, and up to 50 mg once nightly can be prescribed [1].
What are the potential side effects of Quviviq?
Common side effects reported with Quviviq include somnolence (sleepiness), headache, and fatigue. Patients are advised not to drive or engage in other activities requiring complete mental alertness on the day after taking the medication until they have established they can do so safely [1].
Are there any contraindications or precautions for using Quviviq?
Quviviq is contraindicated in patients with narcolepsy due to the risk of significant worsening of daytime somnolence. It should also not be used in patients with a known history of liver disease. Due to the risk of central nervous system (CNS) depression, caution is advised when Quviviq is taken with alcohol or other CNS depressant medications [1].
When does the patent for Quviviq expire?
Information on patent expiry dates for Quviviq is available through resources like DrugPatentWatch.com [2].
Who manufactures Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [1].